292 related articles for article (PubMed ID: 33976146)
1. Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.
Zhang X; Luo M; Dastagir SR; Nixon M; Khamhoung A; Schmidt A; Lee A; Subbiah N; McLaughlin DC; Moore CL; Gribble M; Bayhi N; Amin V; Pepi R; Pawar S; Lyford TJ; Soman V; Mellen J; Carpenter CL; Turka LA; Wickham TJ; Chen TF
Nat Commun; 2021 May; 12(1):2637. PubMed ID: 33976146
[TBL] [Abstract][Full Text] [Related]
2. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
3. CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.
Quayle SN; Girgis N; Thapa DR; Merazga Z; Kemp MM; Histed A; Zhao F; Moreta M; Ruthardt P; Hulot S; Nelson A; Kraemer LD; Beal DR; Witt L; Ryabin J; Soriano J; Haydock M; Spaulding E; Ross JF; Kiener PA; Almo S; Chaparro R; Seidel R; Suri A; Cemerski S; Pienta KJ; Simcox ME
Clin Cancer Res; 2020 Apr; 26(8):1953-1964. PubMed ID: 31964784
[TBL] [Abstract][Full Text] [Related]
4. Use of Engineered Exosomes Expressing HLA and Costimulatory Molecules to Generate Antigen-specific CD8+ T Cells for Adoptive Cell Therapy.
Kim S; Sohn HJ; Lee HJ; Sohn DH; Hyun SJ; Cho HI; Kim TG
J Immunother; 2017 Apr; 40(3):83-93. PubMed ID: 28099196
[TBL] [Abstract][Full Text] [Related]
5. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
6. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
7. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
8. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy.
Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z
Small; 2017 Oct; 13(40):. PubMed ID: 28861943
[TBL] [Abstract][Full Text] [Related]
9. Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes.
Shao J; Xu Q; Su S; Wei J; Meng F; Chen F; Zhao Y; Du J; Zou Z; Qian X; Liu B
Cell Immunol; 2018 Dec; 334():78-86. PubMed ID: 30392890
[TBL] [Abstract][Full Text] [Related]
10. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
[TBL] [Abstract][Full Text] [Related]
11. Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy.
Iriguchi S; Kaneko S
Cancer Sci; 2019 Jan; 110(1):16-22. PubMed ID: 30485606
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15.
McArdel SL; Dugast AS; Hoover ME; Bollampalli A; Hong E; Castano Z; Leonard SC; Pawar S; Mellen J; Muriuki K; McLaughlin DC; Bayhi N; Carpenter CL; Turka LA; Wickham TJ; Elloul S
Cancer Immunol Immunother; 2021 Sep; 70(9):2701-2719. PubMed ID: 34244816
[TBL] [Abstract][Full Text] [Related]
13. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
14. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.
Dowell AC; Oldham KA; Bhatt RI; Lee SP; Searle PF
Cancer Immunol Immunother; 2012 May; 61(5):615-28. PubMed ID: 22021067
[TBL] [Abstract][Full Text] [Related]
15. Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy.
Shao J; Xu Q; Su S; Meng F; Zou Z; Chen F; Du J; Qian X; Liu B
Cell Immunol; 2017 Oct; 320():38-45. PubMed ID: 28935250
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of a cell based artificial antigen-presenting cell for expansion and activation of CD8+ T cells ex vivo.
Gong W; Ji M; Cao Z; Wang L; Qian Y; Hu M; Qian L; Pan X
Cell Mol Immunol; 2008 Feb; 5(1):47-53. PubMed ID: 18318994
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
18. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
19. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
[TBL] [Abstract][Full Text] [Related]
20. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.
Wang C; Lin GH; McPherson AJ; Watts TH
Immunol Rev; 2009 May; 229(1):192-215. PubMed ID: 19426223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
